India's WTO TRIPS waiver proposal gains support from 57 nations

India's push to suspend intellectual property rules around COVID-19 vaccines has picked up backing from fifty-seven countries at the World Trade Organization, according to Piyush Goyal, the Union Minister of Railways, who announced the development on Thursday at an international conference on pharmaceuticals and medical devices.

The proposal, introduced in October 2020 by India and South Africa before the WTO's TRIPS council, seeks a temporary waiver of Trade-Related Aspects of Intellectual Property Rights protections. The goal is straightforward: remove patent barriers that limit which countries can manufacture coronavirus vaccines, allowing broader access to inoculations across the developing world. Goyal framed the growing coalition as evidence that the initiative is gaining momentum, even as developed nations resist what he characterized as an effort to shield pharmaceutical company profits over global health needs.

Speaking at the sixth edition of the India Pharmaceuticals and Medical Devices conference via video, Goyal called on the Indian pharmaceutical industry to champion the waiver publicly. He argued that backing the proposal would accelerate the world's exit from the pandemic by democratizing vaccine production. The minister positioned India as the moral center of this fight, invoking what he called the nation's identity as the "Pharmacy of the World" and suggesting it could become the "Health Capital of World."

The numbers underscore India's actual vaccine reach. More than twenty-five nations have already received Indian-manufactured vaccines, with another forty-nine countries scheduled to receive doses in the coming weeks. The supply chain spans Europe, Latin America, the Caribbean, Africa, Southeast Asia, and the Pacific Islands—a geographic sweep that reflects both India's production capacity and its diplomatic positioning as a supplier to the Global South.

Goyal's remarks carried an implicit challenge to the pharmaceutical industry itself. He praised their pandemic response while simultaneously asking them to embrace a position that would erode their monopoly power. The framing was not accusatory but aspirational: he invited the industry to demonstrate moral leadership by supporting equitable access, suggesting that doing so would define the coming decade for both Indian pharma and the nation's standing in global affairs.

The resistance from developed nations remains the central tension. Goyal did not name specific countries, but his reference to pressure from "the developed world" protecting "some pharmaceutical companies" was unmistakable. The waiver proposal, if adopted, would allow countries without vaccine manufacturing capacity to produce doses without licensing agreements or royalty payments—a direct threat to the patent-based business model that has generated enormous profits for Western pharmaceutical firms.

What remains unresolved is whether the fifty-seven supporting nations can translate their backing into a binding WTO decision. The organization operates by consensus, meaning that even a single dissenting member can block action. The developed world's resistance suggests that consensus may not materialize, at least not without significant negotiation or pressure. For now, India has secured a coalition large enough to keep the proposal alive and to claim momentum, but the outcome remains uncertain.